HC Wainwright Reiterates Buy Rating for Strongbridge Biopharma PLC (SBBP)

Strongbridge Biopharma PLC (NASDAQ:SBBP)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Wednesday. They currently have a $18.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 218.58% from the stock’s current price.

SBBP has been the topic of several other reports. Zacks Investment Research upgraded Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating and set a $7.25 price objective on the stock in a research note on Wednesday, October 11th. ValuEngine lowered Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Oppenheimer Holdings, Inc. began coverage on Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $11.81.

Shares of Strongbridge Biopharma PLC (SBBP) traded up $0.25 on Wednesday, reaching $5.65. The company had a trading volume of 97,220 shares, compared to its average volume of 104,749. Strongbridge Biopharma PLC has a 1 year low of $2.00 and a 1 year high of $8.85. The company has a debt-to-equity ratio of 1.89, a quick ratio of 4.46 and a current ratio of 4.63.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/11/17/hc-wainwright-reiterates-buy-rating-for-strongbridge-biopharma-plc-sbbp.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $114,000. Rhumbline Advisers bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $154,000. California State Teachers Retirement System bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $277,000. Teachers Advisors LLC bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $297,000. Finally, Bank of New York Mellon Corp bought a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth approximately $331,000. Institutional investors and hedge funds own 56.53% of the company’s stock.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply